Chinese herbal medicine Tangshen Formula treatment for type 2 diabetic kidney disease in the early stage: study protocol for a randomized controlled trial

De Jin, Wen-Jing Huang, Xiang Meng, Fan Yang, Qi Bao, Mei-Zhen Zhang, Ya-Nan Yang, Qing Ni, Feng-Mei Lian, Xiao-Lin Tong, De Jin, Wen-Jing Huang, Xiang Meng, Fan Yang, Qi Bao, Mei-Zhen Zhang, Ya-Nan Yang, Qing Ni, Feng-Mei Lian, Xiao-Lin Tong

Abstract

Background: Diabetic kidney disease (DKD) is the main cause of end-stage kidney disease and has become a heavy economic and social burden due to its high prevalence and morbidity. The most effective strategy is that patients with DKD should be diagnosed and treated early. Preliminary studies showed that the Chinese herbal Tangshen Formula (TSF) may delay the progression of DKD, reducing microalbuminuria and macroalbuminuria and improving renal function. We designed a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of TSF in patients with DKD.

Methods/design: This trial is a 13-center, randomized, double-blind, placebo-controlled study. A total of 632 participants will be randomized in a 1:1 ratio to an experiment group (TSF plus losartan) and a control group (placebo plus losartan). The trial cycle will last 24 weeks. The primary outcome will be the change in the urine microalbumin-creatinine ratio from baseline to week 24. The secondary outcome will be the change in the rate of progression to the clinical proteinuria period after intervention, the rate of urine microalbumin negative conversion, the rate of normal urinary microalbumin, the doubling rate of the baseline creatinine value and the glomerular filtration rate between the two groups. Safety in medication will also be evaluated.

Discussion: We hypothesize that patients with type 2 diabetes in the early stage of DKD will benefit from TSF. If successful, this study will provide evidence-based recommendations for clinicians.

Trial registration: ClinicalTrials.gov, NCT03009864. Registered January 2017.

Keywords: Diabetic kidney disease; Randomized controlled trial; Traditional Chinese medicine; Treatment.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow diagram of enrollment, intervention and assessments. TSF Tangshen Formula

References

    1. United States Renal Data System . United States Renal Data System. 2014 USRDS annual data report: epidemiology of kidney disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2014. International comparisons; pp. 188–210.
    1. King P, Peacock I, Donnelly R. The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999;48:643–648. doi: 10.1046/j.1365-2125.1999.00092.x.
    1. Dean J. Organising care for people with diabetes and renal disease. J Ren Care. 2012;38 Suppl 1:23–29. doi: 10.1111/j.1755-6686.2012.00272.x.
    1. Ahmad J. Management of diabetic nephropathy: recent progress and future perspective. Diabetes Metab Syndr. 2015;9(4):343–358. doi: 10.1016/j.dsx.2015.02.008.
    1. Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diab Res Clin Pract. 2018;138:271. doi: 10.1016/j.diabres.2018.02.023.
    1. Li R, Bilik D, Brown MB, et al. Medical costs associated with type 2 diabetes complications and comorbidities. Am J Manag Care. 2013;19(5):421.
    1. American Diabetes Association Glycemic targets: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Supplement 1):S55–S64. doi: 10.2337/dc18-S006.
    1. Jia W, Weng J, Zhu D, et al. Standards of medical care for type 2 diabetes in China 2019. Diabetes Metab Res Rev. 2019:e3158.
    1. Hajhosseiny R, Khavandi K, Jivraj N, Mashayekhi S, Goldsmith DJ, Malik RA. Have we reached the limits for the treatment of diabetic nephropathy? Expert Opin Investig Drugs. 2014;23(4):511–522. doi: 10.1517/13543784.2014.892580.
    1. Dhodi JB, Mestry SN, Juvekar AR. Diabetic nephropathy—genesis, prevention, and treatment. Int J Pharm Pharm Sci. 2014;6(9):42–47.
    1. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310(6):356–360. doi: 10.1056/NEJM198402093100605.
    1. Viberti GC, Hill RD, Jarrett RJ, et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet. 1982;1(8287):1430. doi: 10.1016/S0140-6736(82)92450-3.
    1. Marre M, Chatellier G, Leblanc H, et al. Prevention of siabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ. 1988;297(6656):1092–1095. doi: 10.1136/bmj.297.6656.1092.
    1. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2-diabetes and nephropathy—secondary publication. N Engl J Med. 2008;358(23):2433. doi: 10.1056/NEJMoa0708379.
    1. Brenner BM, Cooper ME, De ZD, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;11(1):861–869. doi: 10.1056/NEJMoa011161.
    1. Tang JL, Liu BY, Ma KW. Traditional Chinese medicine. Lancet. 2008;372(9654):1938–1940. doi: 10.1016/S0140-6736(08)61354-9.
    1. Tian J, Jin D, Qi B, et al. Evidence and Potential Mechanisms of Traditional Chinese Medicine for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-analysis[J]. Diabetes, Obesity and Metabolism. 2019.
    1. Liu Jikai, Henkel Thomas. Traditional Chinese Medicine (TCM): Are Polyphenols and Saponins the Key Ingredients Triggering Biological Activities? Current Medicinal Chemistry. 2002;9(15):1483–1485. doi: 10.2174/0929867023369709.
    1. Letasiová S, Jantová S, Cipák L, et al. Berberine—antiproliferative activity in vitro and induction of apoptosis/necrosis of the U937 and B16 cells. Cancer Lett. 2006;239(2):254. doi: 10.1016/j.canlet.2005.08.024.
    1. Bang JY, Kim KS, Kim EY, et al. Anti-angiogenic effects of the water extract of HangAmDan (WEHAD), a Korean traditional medicine. Sci China Life Sci. 2011;54(3):248–254. doi: 10.1007/s11427-011-4144-3.
    1. Wedge DE, Gao Z, Tabanca N, et al. Chemical composition and biological activities of two Angelica essential oils from China. Planta Med. 2009;75(4):422.
    1. Wang FL, Tang LQ, Yang F, et al. Renoprotective effects of berberine and its possible molecular mechanisms in combination of high-fat diet and low-dose streptozotocin-induced diabetic rats. Mol Biol Rep. 2013;40(3):2405–2418. doi: 10.1007/s11033-012-2321-5.
    1. Zhao XF, Su SJ, Yun G, et al. Mortality and recurrence of vascular disease among stroke patients treated with combined TCM therapy. J Tradit Chin Med. 2012;32(2):173. doi: 10.1016/S0254-6272(13)60007-2.
    1. Chen H, Jing G, Zhao X, et al. Retrospective analysis of the overt proteinuria diabetic kidney disease in the treatment of modified Shenzhuo formula for 2 years. Medicine. 2017;96(12):e6349. doi: 10.1097/MD.0000000000006349.
    1. Guo J, Hongdong C, Xiyan Z, et al. Diabetic kidney disease treated with a modified Shenzhuo formula derived from Traditional Chinese Medicine: a case report. J Tradit Chin Med. 2017;37(6):854–861. doi: 10.1016/S0254-6272(18)30051-7.
    1. Tian J, Zhao L, Zhou Q, et al. Efficacy of Shenzhuo formula on diabetic kidney disease: a retrospective study. J Tradit Chinese Med. 2015;35(5):528. doi: 10.1016/S0254-6272(15)30135-7.
    1. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;63(8):e1–e37. doi: 10.1016/j.jclinepi.2010.03.004.
    1. Boutron I, Altman DG, Moher D, et al. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: a 2017 update and a CONSORT extension for nonpharmacologic trial abstracts. Ann Intern Med. 2017;167(1):40–47. doi: 10.7326/M17-0046.
    1. Chan A.-W., Tetzlaff J. M., Gotzsche P. C., Altman D. G., Mann H., Berlin J. A., Dickersin K., Hrobjartsson A., Schulz K. F., Parulekar W. R., Krleza-Jeric K., Laupacis A., Moher D. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346(jan08 15):e7586–e7586. doi: 10.1136/bmj.e7586.
    1. National Kidney Foundation KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60(5):850–886. doi: 10.1053/j.ajkd.2012.07.005.
    1. Levin A, Stevens PE, Bilous RW, et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–150. doi: 10.1038/kisup.2012.73.
    1. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892–1903. doi: 10.1056/NEJMoa1303154.
    1. Montero de Francisco A, García-Luque A, Fernandez M, Puerro M. Side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: are we facing a new syndrome. Am J Cardiol. 2012;110(10):1552–1553. doi: 10.1016/j.amjcard.2012.08.027.
    1. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983;32(Suppl 2):64–78. doi: 10.2337/diab.32.2.S64.
    1. Piccoli GB, Grassi G, Cabiddu G, Nazha M, Roggero S, Capizzi I, et al. Diabetic kidney disease: a syndrome rather than a single disease. Rev Diabet Stud. 2015;12(1–2):87–109. doi: 10.1900/RDS.2015.12.87.
    1. Tong X, Xu J, Lian F. Structural alteration of gut microbiota during the amelioration of human type 2 diabetes with hyperlipidemia by metformin and a traditional Chinese herbal formula: a multicenter, randomized, open label clinical trial. Mbio. 2018;9(3):3–7.
    1. Yu X, Xu L, Zhou Q, et al. The efficacy and safety of the Chinese herbal formula, JTTZ, for the treatment of type 2 diabetes with obesity and hyperlipidemia: a multicenter randomized, positive-controlled, open-label clinical trial. Int J Endocrinol. 2018;2018(1):9519231.
    1. Tian J, Lian F, Yu X, et al. The efficacy and safety of Chinese herbal decoction in type 2 diabetes: a 5-year retrospective study. Evid Based Complement Alternat Med. 2016;2016(9):5473015.
    1. Lian F, Tian J, Chen X, et al. The efficacy and safety of Chinese herbal medicine Jinlida as add-on medication in type 2 diabetes patients ineffectively managed by metformin monotherapy: a double-blind, randomized, placebo-controlled, multicenter trial. PLoS One. 2015;10(6):e0130550. doi: 10.1371/journal.pone.0130550.
    1. Xu J, Lian F, Zhao L, et al. Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula. ISME J. 2015;9(3):552–562. doi: 10.1038/ismej.2014.177.
    1. Ji L, Tong X, Wang H, et al. Efficacy and safety of traditional Chinese medicine for diabetes: a double-blind, randomised, controlled trial. PLoS One. 2013;8(2):e56703. doi: 10.1371/journal.pone.0056703.
    1. He L, Wang H, Gu C, et al. Administration of traditional Chinese blood circulation activating drugs for microvascular complications in patients with type 2 biabetes mellitus. J Diabetes Res. 2016;2016(10):1–9.
    1. Lian F, Wu L, Tian J, et al. The effectiveness and safety of a danshen-containing Chinese herbal medicine for diabetic retinopathy: a randomized,double-blind,placebo-controlled multicenter clinical trial. J Ethnopharmacol. 2015;164:71–77. doi: 10.1016/j.jep.2015.01.048.
    1. Lin MY, Chiu YW, Chang JS, Lin HL, Lee CT, Chiu GF, Kuo MC, Wu MT, Chen HC, Hwang SJ. Association of prescribed Chinese herbal medicine use with risk of end-stage renal disease in patients with chronic kidney disease. Kidney Int. 2015;88(6):1365–1373. doi: 10.1038/ki.2015.226.
    1. Fan XM, Huang CL, Wang YM, et al. Therapeutic effects of Tangshen Formula on diabetic nephropathy in db/db mice using cytokine antibody array. J Diabetes Res. 2018;2018(3):1–10. doi: 10.1155/2018/8237590.
    1. Zhao TT, Sun SF, Zhang HJ, et al. Therapeutic effects of Tangshen Formula on diabetic nephropathy in rats. PLoS One. 2016;11(1):e0147693. doi: 10.1371/journal.pone.0147693.
    1. Huang M, Zhu C, Liang QL, et al. Effect of Tangshen Formula on phospholipids metabolism in diabetic nephropathy patients. Acta Pharmaceutica Sinica. 2011;46(7):780.
    1. Miranda-Díaz Alejandra Guillermina, Pazarín-Villaseñor Leonardo, Yanowsky-Escatell Francisco Gerardo, Andrade-Sierra Jorge. Oxidative Stress in Diabetic Nephropathy with Early Chronic Kidney Disease. Journal of Diabetes Research. 2016;2016:1–7. doi: 10.1155/2016/7047238.
    1. Kashihara N, Haruna Y, Kondeti VK, et al. Oxidative stress in diabetic nephropathy. Curr Med Chem. 2010;17(34):4256–4269. doi: 10.2174/092986710793348581.
    1. Pathak JV, Dass EE. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy. Indian J Pharmacol. 2015;47(2):148–152. doi: 10.4103/0253-7613.153420.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit